Business UpdateJul 21, 2026, 07:32 AM
Abeona Activates Cincinnati Children's as 7th ZEVASKYN QTC
AI Summary
Abeona Therapeutics announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center (QTC) for ZEVASKYN® (prademagene zamikeracel). This expansion aims to increase access to the company's autologous gene-modified cellular sheets, which are the first and only treatment for wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). Cincinnati Children's is a major EB center, and this collaboration is expected to significantly benefit RDEB patients.
Key Highlights
- Abeona activated Cincinnati Children's as the seventh ZEVASKYN Qualified Treatment Center (QTC).
- ZEVASKYN is the first and only autologous gene-modified cellular sheet for RDEB wounds.
- Cincinnati Children's is one of the largest Epidermolysis Bullosa (EB) centers in the US.
- ZEVASKYN treats recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder.
- Abeona Assist offers comprehensive patient support, including financial and logistical aid.
- ZEVASKYN works by incorporating the COL7A1 gene into a patient's own skin cells.
- Potential risks include serious allergic reactions and a potential contribution to cancer development.
Price Impact
More from ABEO